Tizanidine Induced Hypotension: Report of a Case and Review of the
Literature

Roopali      Mahajan; Jayantee      Kalita

doi:10.2174/1574886318666230725113855

Abstract

Introduction: Spasticity is a common sequelae of stroke, and often these patients receive anti-spastic drugs such as baclofen or tizanidine. Stroke patients have multiple co-morbidities such as hypertension, diabetes, and seizure. Tizanidine is an α2 and imidazole receptor agonist at a spinal and supraspinal level resulting in reduced central sympathetic outflow and causing hypotension rarely, especially in those receiving beta-blockers or angiotensin-converting enzyme inhibitors.

Case Presentation: We report a 56-year-old hypertensive male presenting with altered sensorium who had recurrent intracerebral hemorrhage with left spastic hemiplegia and focal seizures. He was on amlodipine, atenolol, telmisartan and oxcarbazepine. After 3 doses of tizanidine 2mg, his blood pressure dropped from 140/90 to 80/40 mmHg and pulse from 82 bpm to 44 bpm. His blood counts, serum chemistry, procalcitonin, and Trop I were normal. ECG revealed sinus bradycardia. After 8 hours of withdrawing tizanidine, his blood pressure became 110/70 mmHg, and on the next day, it became 140/82 mmHg. His attendants were taught physiotherapy to minimize spasticity.

Conclusion: This patient highlights the need for close monitoring of patients receiving tizanidine co-medication with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. These drugs have a synergistic effect on reducing the renin-angiotensin-aldosterone system, thereby hypotension and bradycardia.

« Previous

Graphical Abstract

[1]
Donkor ES. Stroke in the 21st century: A snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat  2018; 2018: 3238165.

[2]
Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology  2013; 80(3) (Suppl. 2): S13-9.
 [http://dx.doi.org/10.1212/WNL.0b013e3182762448] [PMID:  23319481]

[3]
Bavikatte G, Subramanian G, Ashford S, Allison R, Hicklin D. Early identification, intervention and management of post-stroke spasticity: expert consensus recommendations. J Cent Nerv Syst Dis  2021; 13: 11795735211036576.

[4]
Honda M, Sekiguchi Y, Sato N, Ono H. Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine. Eur J Pharmacol  2002; 445(3): 187-93.
 [http://dx.doi.org/10.1016/S0014-2999(02)01664-3] [PMID:  12079683]

[5]
Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br J Clin Pharmacol  2004; 57(3): 349-53.
 [http://dx.doi.org/10.1046/j.1365-2125.2003.02028.x] [PMID:  14998432]

[6]
Wagstaff AJ, Bryson HM. Tizanidine. Drugs  1997; 53(3): 435-52.
 [http://dx.doi.org/10.2165/00003495-199753030-00007] [PMID:  9074844]

[7]
Kamen L, Henney HR III, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin  2008; 24(2): 425-39.
 [http://dx.doi.org/10.1185/030079908X261113] [PMID:  18167175]

[8]
Chaugai S, Dickson AL, Shuey MM, et al. Co‐Prescription of strong cyp 1a2 inhibitors and the risk of tizanidine‐associated hypotension: A retrospective cohort study. Clin Pharmacol Ther  2019; 105(3): 703-9.
 [http://dx.doi.org/10.1002/cpt.1233] [PMID:  30223305]

[9]
Kao CD, Chang JB, Chen JT, Wu ZA, Shan DE, Liao KK. Hypotension due to interaction between lisinopril and tizanidine. Ann Pharmacother  2004; 38(11): 1840-3.
 [http://dx.doi.org/10.1345/aph.1E161] [PMID:  15383642]

[10]
Momo K, Homma M, Abei M, Hyodo I, Kohda Y. Tizanidine-induced hypotension in patients with liver cirrhosis. Eur J Clin Pharmacol  2008; 64(6): 647-8.
 [http://dx.doi.org/10.1007/s00228-008-0469-7] [PMID:  18320182]

[11]
Publow SW, Branam DL. Hypotension and bradycardia associated with concomitant tizanidine and lisinopril therapy. Am J Health Syst Pharm  2010; 67(19): 1606-10.
 [http://dx.doi.org/10.2146/ajhp090657] [PMID:  20852161]

[12]
Johnson TR, Tobias JD. Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension. J Child Neurol  2000; 15(12): 818-9.
 [http://dx.doi.org/10.1177/088307380001501211] [PMID:  11198499]

[13]
Farrell MC, Biaggioni I, Shibao CA. Neurogenic orthostatic hypotension induced by tizanidine. Clin Auton Res  2020; 30(2): 173-5.
 [http://dx.doi.org/10.1007/s10286-019-00637-5] [PMID:  31535247]

[14]
Goyal L, Mallick D, Zapata MR, Yashi K, Chourasia P, Surani S. Tizanidine toxicity from ciprofloxacin: A cautionary tale. Cureus  2022; 14(12): e32492.
 [http://dx.doi.org/10.7759/cureus.32492] [PMID:  36644068]

[15]
Regulski M, Regulska K, Stanisz BJ, et al. Chemistry and pharmacology of Angiotensin-converting enzyme inhibitors. Curr Pharm Des  2015; 21(13): 1764-75.
 [http://dx.doi.org/10.2174/1381612820666141112160013] [PMID:  25388457]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1574886318666230725113855	Print ISSN 1574-8863
Publisher Name Bentham Science Publisher	Online ISSN 2212-3911

Current Drug Safety

Tizanidine Induced Hypotension: Report of a Case and Review of the Literature

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract